TrialInternational journal of hematology2023

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.

Noriko Fukuhara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.